Abstract:Background The genes for the long QT syndrome (LQTS) linked to chromosomes 3 (LQT3) and 7 (LQT2) were identified as SCN5A , the cardiac Na + channel gene, and as HERG , a K + channel gene. These findings opened the possibility of attempting gene-specific control of ventricular repolarization. We tested the hypothesis that the QT interval would shorten more in LQT3 than in LQT2 patients in response to mexiletine and also in response to increases in heart rate. Methods and Results Fifteen LQTS patients were studied. Six LQT3 and 7 LQT2 patients were treated with mexiletine, and its effects on QT and QT c were measured. Mexiletine significantly shortened the QT interval among LQT3 patients (QT c from 535±32 to 445±31 ms, P <.005) but not among LQT2 patients (QT c from 530±79 to 503±60 ms, P =NS). LQT3 patients (n=7) shortened their QT interval in response to increases in heart rate much more than LQT2 patients (n=4) and also more than 18 healthy control subjects (9.45±3.3 versus 3.95±1.97 and 2.83±1.33, P <.05; data expressed as percent reduction in QT per 100-ms shortening in RR). Among these patients, there is also a trend for LQT2 patients to have syncope or cardiac arrest under emotional or physical stress and for LQT3 patients to have cardiac events either at rest or during sleep. Conclusions This is the first study to demonstrate differential responses of LQTS patients to interventions targeted to their specific genetic defect. These findings also suggest that LQT3 patients may be more likely to benefit from Na + channel blockers and from cardiac pacing because they would be at higher risk of arrhythmia at slow heart rates. Conversely, LQT2 patients may be at higher risk to develop syncope under stressful conditions because of the combined arrhythmogenic effect of catecholamines with the insufficient adaptation of their QT interval when heart rate increases.

A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome

Identification of A Kir3.4 Mutation in Congenital Long Qt Syndrome

Long-QT Syndrome-Associated Missense Mutations in the Pore Helix of the HERG Potassium Channel

Location of mutation in the KCNQ1 and phenotypic presentation of long QT syndrome.

A Novel Splice Mutation of HERG in a Chinese Family with Long QT Syndrome.

Genetics, Molecular Mechanisms and Management of Long QT Syndrome

Molecular Genetics of Long QT Syndrome from Genes to Patients

The Molecular Basis of Long QT Syndrome and Prospects for Therapy.

A Missense Mutation (G604S) in the S5/pore Region of HERG Causes Long QT Syndrome in a Chinese Family with a High Incidence of Sudden Unexpected Death

Long QT Syndrome-associated Mutations in the Per-Arnt-Sim (PAS) Domain of HERG Potassium Channels Accelerate Channel Deactivation

Novel HERG Gene Mutation and Congenital Long QT Syndrome

Three Novel Mutations of Potassium Channel HERG and SCN5A in Chinese Families of Congenital Long QT Syndromes

A Novel Deletion-Frameshift Mutation in the S1 Region of HERG Gene in a Chinese Family with Long QT Syndrome.

Identification and characterization of two novel KCNH2 mutations contributing to long QT syndrome

Association of Ion Channel Genes KCNQ1 and KCNH2 with Congenital Long-QT Syndrome

Novel Compound Heterozygous Mutations in the KCNQ1 Gene Associated with Autosomal Recessive Long QT Syndrome (jervell and Lange‐Nielsen Syndrome)

Α-1-syntrophin Mutation and the Long-QT Syndrome

Mutations in conserved amino acids in the KCNQ1 channel and risk of cardiac events in type-1 long-QT syndrome.

Characterization Of A Kcnq1/Kvlqt1 Polymorphism In Asian Families With Lqt2: Implications For Genetic Testing

Clinical Aspects of Type-1 Long-Qt Syndrome by Location, Coding Type, and Biophysical Function of Mutations Involving the KCNQ1 Gene.

Long QT Syndrome Patients With Mutations of the SCN5A and HERG Genes Have Differential Responses to Na + Channel Blockade and to Increases in Heart Rate